Parkinson's

Follow
Scientific illustration depicting the TMEM175 lysosomal ion channel preventing over-acidification and toxic buildup in neurons, relevant to Parkinson’s disease research.
Image generated by AI

Study links lysosomal ion channel TMEM175 to protection against over-acidification, with implications for Parkinson’s research

Reported by AI Image generated by AI Fact checked

Researchers at LMU Munich, Bonn-Rhein-Sieg University of Applied Sciences, TU Darmstadt and Nanion Technologies report that the lysosomal ion channel TMEM175 helps prevent excessive acidification inside lysosomes, a malfunction that the team says could contribute to toxic buildup associated with Parkinson’s disease. The findings were reported in the Proceedings of the National Academy of Sciences.

Researchers at Emory University have discovered that excessive brain and muscle activity during minor balance disruptions contributes to poorer balance recovery in older adults, including those with Parkinson's disease. The study, published in eNeuro, reveals that trying harder to balance may actually increase fall risk. Opposing muscles stiffening simultaneously further impairs stability.

Reported by AI

Michael J. Fox guest stars in Shrinking season 3 as Gerry, a Parkinson's patient who befriends Harrison Ford's Paul—sometimes real, sometimes a hallucination. The role reunites Fox with creator Bill Lawrence from Spin City and spotlights Parkinson's challenges.

Researchers in Sweden and Norway have identified biological markers in the blood that signal the earliest stages of Parkinson's disease, potentially allowing detection up to 20 years before motor symptoms appear. The study, published in npj Parkinson's Disease, highlights a brief window where these markers are detectable, offering hope for earlier diagnosis and treatment. Blood tests based on this discovery could enter healthcare testing within five years.

Reported by AI Fact checked

Researchers at Case Western Reserve University report they have identified an abnormal interaction between the Parkinson’s-linked protein alpha-synuclein and the enzyme ClpP that disrupts mitochondrial function in experimental models. They also describe an experimental compound, CS2, designed to block that interaction, which they say improved movement and cognitive performance and reduced brain inflammation in lab and mouse studies.

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline